Creative Biolabs: The Right Solution to Boost Anti-Monkeypox Drug Discovery Effort

Creative Biolabs: The Right Solution to Boost Anti-Monkeypox Drug Discovery Effort

Creative Biolabs: The Right Solution to Boost Anti-Monkeypox Drug Discovery Effort

In May 2022, the outbreak and rapid spread of the monkeypox virus caused many deaths, posing significant threats to human health. Despite extensive research into new therapies and drugs, no viable treatment has been developed yet. Hence, Creative Biolabs is committed to discovering a solution to this urgent problem that affects all of humanity. A group of elite scientists embarks on its journey with cutting-edge discovery platforms, which enable Creative Biolabs to create well-rounded anti-monkeypox drug discovery solutions and provide clients with scientific and technical assistance, helping them to proceed with their projects.

“Monkeypox and smallpox are both poxviruses that belong to the family Poxviridae,” commented an expert at Creative Biolabs, “and it is well known that vaccines contribute to the eradication of smallpox, one of the deadliest viral diseases for human health. Hence, vaccine development is equally important in fighting against monkeypox viruses.”

As an expert in pre-clinical vaccine development with over a decade of experience, Creative Biolabs enhanced its investment in monkeypox vaccines, which are considered the most effective and safest therapy methods, while maintaining traditional and advanced technologies to design and develop effective vaccine-based anti-monkeypox drug discovery solutions, meeting clients’ specific development demands.

Embracing the wide range of studies in antiviral drug discovery, Creative Biolabs creates different solutions to meet diverse anti-monkeypox drug discovery demands,

“Clients might confront various challenges when working on nucleic acid-based anti-monkeypox drug discovery,” added the scientist, “but our comprehensive discovery platform is designed to help clients tackle these problems.”

Creative Biolabs works with clients to provide integrated nucleic acid-based anti-monkeypox drug discovery solutions, including solutions for oligonucleotides, ribozymes, deoxyribozymes, and RNA interference molecules. In addition, the company also provides drug discovery solutions for extensive drug targets, such as viral nucleic acid, viral polymerase, protease, entry/fusion protein, interferon, and cellular target, proceeding with global clients’ anti-monkeypox drug discovery against different drug targets.  

To learn more about advanced anti-monkeypox drug discovery solutions at Creative Biolabs, please visit https://monkeypox.creative-biolabs.com/.

About Creative Biolabs

As a world-leading service provider devoted to drug discovery solutions for years, Creative Biolabs has updated a series of innovative anti-monkeypox drug discovery solutions by combining its leading expertise in drug discovery with creative approaches. Creative Biolabs works with clients to overcome development challenges and drive discovery processes to success.

About Creative Biolabs

As a world-leading service provider devoted to drug discovery solutions for years, Creative Biolabs has updated a series of innovative anti-monkeypox drug discovery solutions by combining its leading expertise in drug discovery with creative approaches. Creative Biolabs works with clients to overcome development challenges and drive discovery processes to success.

Media Contact

Company Name
Creative Biolabs
Contact Name
Candy Swift
State
New York
Country
United States
Website
https://www.creative-biolabs.com/

About Post Author